Galera Therapeutics, Inc.
GRTX
$0.09
$0.00-4.61%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -44.16% | -48.25% | -47.57% | -37.31% | -49.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.31% | -57.31% | -65.23% | -66.21% | -69.35% |
| Operating Income | 50.31% | 57.31% | 65.23% | 66.21% | 69.35% |
| Income Before Tax | 1,010.36% | 877.92% | 54.65% | 54.02% | 64.22% |
| Income Tax Expenses | -- | -- | 100.00% | -- | -- |
| Earnings from Continuing Operations | 1,021.79% | 886.25% | 54.18% | 54.72% | 64.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,021.79% | 886.25% | 54.18% | 54.72% | 64.66% |
| EBIT | 50.31% | 57.31% | 65.23% | 66.21% | 69.35% |
| EBITDA | 64.73% | 57.39% | 64.84% | 65.94% | 69.19% |
| EPS Basic | 342.47% | 290.72% | 67.46% | 65.08% | 72.96% |
| Normalized Basic EPS | 68.38% | 76.87% | 81.26% | 78.97% | 81.28% |
| EPS Diluted | 342.47% | 290.72% | 67.46% | 65.08% | 72.96% |
| Normalized Diluted EPS | 68.38% | 76.87% | 81.26% | 78.97% | 81.28% |
| Average Basic Shares Outstanding | 50.02% | 80.30% | 61.27% | 47.02% | 33.21% |
| Average Diluted Shares Outstanding | 50.02% | 80.30% | 61.27% | 47.02% | 33.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |